micafungin + fluconazole + liposomal amphotericin B + caspofungin
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Liver Transplantation
Conditions
Liver Transplantation, Mycoses
Trial Timeline
Dec 15, 2009 → May 3, 2012
NCT ID
NCT01058174About micafungin + fluconazole + liposomal amphotericin B + caspofungin
micafungin + fluconazole + liposomal amphotericin B + caspofungin is a phase 3 stage product being developed by Astellas Pharma for Liver Transplantation. The current trial status is completed. This product is registered under clinical trial identifier NCT01058174. Target conditions include Liver Transplantation, Mycoses.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01058174 | Phase 3 | Completed |
Competing Products
20 competing products in Liver Transplantation